Matthew D. Tucker

2.2k total citations · 1 hit paper
29 papers, 1.0k citations indexed

About

Matthew D. Tucker is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Matthew D. Tucker has authored 29 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 5 papers in Surgery. Recurrent topics in Matthew D. Tucker's work include Cancer Immunotherapy and Biomarkers (11 papers), Renal cell carcinoma treatment (9 papers) and Prostate Cancer Treatment and Research (7 papers). Matthew D. Tucker is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Renal cell carcinoma treatment (9 papers) and Prostate Cancer Treatment and Research (7 papers). Matthew D. Tucker collaborates with scholars based in United States, United Kingdom and Canada. Matthew D. Tucker's co-authors include Shahrzad Noorbaloochi, Jasvinder A. Singh, George A. Wells, Peter Tugwell, Elizabeth Tanjong Ghogomu, Robin Christensen, Chris Cameron, Tammy Clifford, Doug Coyle and Brian I. Rini and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Matthew D. Tucker

28 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis

2015 441 citations Jasvinder A. Singh, Chris Cameron et al. The Lancet profile →

Peers

Countries citing papers authored by Matthew D. Tucker

Since Specialization

Citations

This map shows the geographic impact of Matthew D. Tucker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew D. Tucker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew D. Tucker more than expected).

Fields of papers citing papers by Matthew D. Tucker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew D. Tucker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew D. Tucker. The network helps show where Matthew D. Tucker may publish in the future.

Co-authorship network of co-authors of Matthew D. Tucker

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew D. Tucker. A scholar is included among the top collaborators of Matthew D. Tucker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew D. Tucker. Matthew D. Tucker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma 2022 ·Cancers ·Yu‐Wei Chen, Matthew D. Tucker, Landon C. Brown, (unknown), Kristin Kathleen Ancell, Andrew J. Armstrong, Kathryn E. Beckermann, Nancy B. Davis, Michael R. Harrison, (unknown), (unknown), Kerry Schaffer, (unknown), Daniel J. George, W. Kimryn Rathmell, Brian I. Rini, Tian Zhang	12
2	Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC). 2022 ·Journal of Clinical Oncology ·Yu‐Wei Chen, Matthew D. Tucker, Landon C. Brown, (unknown), Kristin Kathleen Ancell, Andrew J. Armstrong, (unknown), Nancy B. Davis, Michael R. Harrison, (unknown), (unknown), Kerry Schaffer, (unknown), (unknown), W. Kimryn Rathmell, Brian I. Rini, Tian Zhang	1
3	Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma 2021 ·Biomarker Research ·Matthew D. Tucker, Landon C. Brown, Yu‐Wei Chen, Chester Kao, (unknown), Emily N. Kinsey, Kristin Kathleen Ancell, Kathryn E. Beckermann, Nancy B. Davis, (unknown), Kerry Schaffer, Andrew J. Armstrong, Michael R. Harrison, Daniel J. George, W. Kimryn Rathmell, Brian I. Rini, Tian Zhang	28
4	A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab 2021 ·Targeted Oncology ·Kunal Desai, Landon C. Brown, Wei Wei, Matthew D. Tucker, Chester Kao, Emily N. Kinsey, Brian I. Rini, Kathryn E. Beckermann, Tian Zhang, Moshe Chaim Ornstein	12
5	Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer 2021 ·Prostate Cancer and Prostatic Diseases ·Andrew J. Armstrong, Xiaotong Li, Matthew D. Tucker, Shantao Li, Xinmeng Jasmine Mu, Kenneth Eng, Andrea Sboner, Mark A. Rubin, Mark Gerstein	4
6	Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT). 2021 ·Journal of Clinical Oncology ·Matthew D. Tucker, Andrew Schmidt, Chih–Yuan Hsu, Yu Shyr, Andrew J. Armstrong, Ziad Bakouny, Christina Chapman, Scott J. Dawsey, Benjamin A. Gartrell, Susan Halabi, Monika Joshi, Ali Raza Khaki, Harry Menon, Matthew Puc, Nima Sharifi, Justin Shaya, Elizabeth Wulff‐Burchfield, Tian Zhang, Shilpa Gupta, Rana R. McKay, (unknown)	6
7	Outcomes with novel combinations in non-clear cell renal cell carcinoma(nccRCC): ORACLE study. 2021 ·Journal of Clinical Oncology ·Deepak Kilari, Anikó Szabó, Pooja Ghatalia, Tracy L. Rose, (unknown), Matthew D. Tucker, Ariel Ann Nelson, (unknown), (unknown), (unknown), Rohit Jain, Benjamin L. Maughan, Ajjai Alva, Abhishek Tripathi, Arnab Basu, Vadim S. Koshkin, Hamid Emamekhoo, Nancy B. Davis, Arpita Desai, Rana R. McKay	0
8	LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types 2021 ·Journal for ImmunoTherapy of Cancer ·Landon C. Brown, Matthew D. Tucker, Ramy Sedhom, Eric Schwartz, Jason Zhu, Chester Kao, Matthew Labriola, Rajan T. Gupta, Daniele Marin, Yuan Wu, Santosh Gupta, Tian Zhang, Michael R. Harrison, Daniel J. George, Ajjai Alva, Emmanuel S. Antonarakis, Andrew J. Armstrong	73
9	Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma 2020 ·Cancers ·Matthew D. Tucker, Brian I. Rini	34
10	Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types. 2020 ·Journal of Clinical Oncology ·Landon C. Brown, Ramy Sedhom, Eric Schwartz, Jason Zhu, Chester Kao, Matthew D. Tucker, Matthew Labriola, Rajan T. Gupta, Daniele Marin, Yuan Wu, Tian Zhang, Michael R. Harrison, Daniel J. George, Ajjai Alva, Emmanuel S. Antonarakis, Andrew J. Armstrong	5
11	Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer 2019 ·Cancer Medicine ·Matthew D. Tucker, Jason Zhu, Daniele Marin, Rajan T. Gupta, Santosh Gupta, William R. Berry, Sundhar Ramalingam, Tian Zhang, Michael R. Harrison, Yuan Wu, Patrick Healy, (unknown), Daniel J. George, Andrew J. Armstrong	59
12	Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer 2019 ·Urologic Oncology Seminars and Original Investigations ·Jason Zhu, Matthew D. Tucker, Daniele Marin, Rajan T. Gupta, Patrick Healy, Michael Humeniuk, Casey A. Jarvis, (unknown), Megan McNamara, Daniel J. George, Yuan Wu, (unknown), Andrew J. Armstrong	17
13	A systematic review of clinical pharmacist interventions in paediatric hospital patients 2018 ·European Journal of Pediatrics ·Aaron Drovandi, (unknown), Matthew D. Tucker, (unknown), (unknown), Therése Kairuz	43
14	Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer 2017 ·Clinical Genitourinary Cancer ·Jason Zhu, Matthew D. Tucker, Endi Wang, (unknown), Andrew J. Armstrong, Daniel J. George, Tian Zhang	6
15	Photoimmunotherapy of residual disease after incomplete surgical resection in head and neck cancer models 2016 ·Cancer Medicine ·Lindsay S. Moore, Esther de Boer, Jason M. Warram, Matthew D. Tucker, William R. Carroll, Melissa L. Korb, Margaret Brandwein‐Gensler, Gooitzen M. van Dam, Eben L. Rosenthal	31
16	In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas 2015 ·Scientific Reports ·Esther de Boer, Jason M. Warram, Matthew D. Tucker, Yolanda E. Hartman, Lindsay S. Moore, Johannes S. de Jong, Thomas K. Chung, Melissa L. Korb, Kurt R. Zinn, Gooitzen M. van Dam, Eben L. Rosenthal, Margaret Brandwein‐Gensler	76
17	Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis breakdown → 2015 ·The Lancet ·Jasvinder A. Singh, Chris Cameron, Shahrzad Noorbaloochi, (unknown), Matthew D. Tucker, Robin Christensen, Elizabeth Tanjong Ghogomu, Doug Coyle, Tammy Clifford, Peter Tugwell, George A. Wells	441
18	Belimumab for systemic lupus erythematosus 2013 ·Cochrane Database of Systematic Reviews ·Jasvinder A. Singh, Shahrzad Noorbaloochi, Matthew D. Tucker	6
19	The Bristol ‘OA500 study’: progression and impact of the disease after 8 years 2000 ·Osteoarthritis and Cartilage ·Paul Dieppe, J Cushnaghan, Matthew D. Tucker, Simone Browning, Lee Shepstone	109
20	Does patient education in rheumatoid arthritis have therapeutic potential? 1991 ·Annals of the Rheumatic Diseases ·Matthew D. Tucker, John Kirwan	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact